Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00354562 · ClinicalTrials.gov registry record · Phase 1
A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT00354562 is a Phase 1 study that was terminated before completion, run by Abbott. The registered enrollment target is 75 participants.
The verdict
NCT00354562, a Phase 1 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
To determine the efficacy of ABT-751 when administered in combination with standard docetaxel in subjects with advanced or metastatic NSCLC.
Interventions
- DRUG Placebo
- DRUG Docetaxel
- DRUG ABT-751
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2007-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00354562
The ClinicalTrials.gov registry entry for NCT00354562 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00354562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00354562 about?
NCT00354562 is a clinical study titled "A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer". To determine the efficacy of ABT-751 when administered in combination with standard docetaxel in subjects with advanced or metastatic NSCLC.
What is the current status of trial NCT00354562?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2007-02.
What interventions are being tested in trial NCT00354562?
The interventions under investigation include: Placebo (DRUG), Docetaxel (DRUG), ABT-751 (DRUG).
Who is sponsoring clinical trial NCT00354562?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.